|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy显示文摘AIM To report early imaging assessment of ablated area post electrochemotherapy(ECT) in patients with locally advanced pancreatic cancer(LAPC). METHODS ECT was performed in 19 LAPC patients enrolled in an approved ongoing clinical phase Ⅰ/Ⅱ study. Before and after ECT, 18 patients underwent computed tomography(CT) scan, 11 patients underwent morphological and functional magnetic resonance(MR) scan(dynamic contrast enhanced-MRI) calculating wash-in slope(WIS) and wash-out slope(WOS); diffusion weighted imaging calculating pseudo-diffusivity(Dp), perfusion fraction(fp) and tissue diffusivity(Dt); 10 patients underwentpositron emission tomography(PET). Response evaluation criteria in solid tumour(RECIST) on MR and CT were used to assess tumour therapy response. Choi on CT, PET response criteria in solid tumors(PERCIST) on PET and functional parameters on MR were used to evaluate treatment response.RESULTS For each patient no significant reduction was measurable by CT and MR using RECIST. According Choi criteria a partial response was obtained in 18/18(100.0%) patients. According PERCIST criteria 6/10(60.0%) patients showed a partial response, 3/10(30.0%) stable disease and 1/10(10.0%) progression disease. Moreover, using functional MR parameters, a significant reduction of viable tumour after ECT can be observed. According ΔWIS and ΔWOS 9/11(81.8%) patients exhibited a partial response and 2/11(18.2%) stable disease; 8/11(72.7%) patients were considered in partial response by ΔDp evaluation and 3/11(27.3%) in stable disease; according ΔDt 7/11(63.6%) patients showed a partial response, 1/11(9.1%) showed progression of disease and 3/11(27.3%) were stable. Perfusion fraction fp showed a significant reduction after ECT only in four patients. No significant difference was observed after ECT in signal intensity of T1-weighted images and T2-weighted images, and in equilibrium-phase of contrast study, according to χ2 test was observed. A good correlation was reported between ΔHounsfield unit and Δmaximum standardized uptake value and between Δfp and ΔWOS, with a significant statistically difference(P < 0.05) using Spearman correlation coefficient.CONCLUSION Perfusion and diffusion MR derived parameters, Choi, PERCIST criteria are more performant than morphological MR and CT criteria to assess ECT treatment response. | Vincenza Granata Roberta Fusco Sergio Venanzio Setola Mauro Piccirillo Maddalena Leongito Raffaele Palaia Francesco Granata Secondo Lastoria Francesco Izzo Antonella Petrillo | 2017 | World Journal of Gastroenterology2017，23，26： | 3 |
| 2 | Molecular identification of nontuberculous mycobacteria isolates in a Brazilian mycobacteria reference laboratory显示文摘 | Ana Roberta Fusco da Costa Maria Luiza Lopes Ismari Perini Furlaneto Maísa Silva de Sousa Karla Valéria Batista Lima | 2010 | Diagnostic Microbiology & Infectious Disease2010，，4： | 1 |
| 3 | Local ablation of pancreatic tumors: State of the art and future perspectives显示文摘BACKGROUND Currently,the technologies most commonly used to treat locally advanced pancreatic cancer are radiofrequency ablation(RFA),microwave ablation,and irreversible(IRE)or reversible electroporation combined with low doses of chemotherapeutic drugs.AIM To report an overview and updates on ablative techniques in pancreatic cancer.METHODS Several electronic databases were searched.The search covered the years from January 2000 to January 2021.Moreover,the reference lists of the found papers were analysed for papers not indexed in the electronic databases.All titles and abstracts were analysed.RESULTS We found 30 studies(14 studies for RFA,3 for microwave therapy,10 for IRE,and 3 for electrochemotherapy),comprising 1047 patients,which were analysed further.Two randomized trials were found for IRE.Percutaneous and laparotomy approaches were performed.In the assessed patients,the median maximal diameter of the lesions was in the range of 2.8 to 4.5 cm.All series included patients unfit for surgical treatment,but Martin et al assessed a subgroup of patients with borderline resectable tumours who underwent resection with margin attenuation with IRE.Most studies administered chemotherapy prior to ablative therapies.However,several studies suggest that the key determinant of improved survival is attributable to ablative treatment alone.Nevertheless,the authors suggested chemotherapy before local therapies for several reasons.This strategy may not only downstage a subgroup of patients to curative-intent surgery but also support to recognize patients with biologically unfavourable tumours who would likely not benefit from ablation treatments.Ablation therapies seem safe based on the 1047 patients assessed in this review.The mortality rate ranged from 1.8%to 2%.However,despite the low mortality,the reported rates of severe post procedural complications ranged from 0%-42%.Most reported complications have been self-limiting and manageable.Median overall survival varied between 6.0 and 33 mo.Regarding the technical success rate,assessed papers reported an estimated rate in the range of 85%to 100%.However,the authors reported early recurrence after treatment.A distinct consideration should be made on whether local treatments induce an immune response in the ablated area.Preclinical and clinical studies have shown that RFA is a promising mechanism for inducing antigen-presenting cell infiltration and enhancing the systemic antitumour T-cell immune response and tumour regression.CONCLUSION In the management of patients with pancreatic cancer,the possibility of a multimodal approach should be considered,and conceptually,the combination of RFA with immunotherapy represents a novel angle of attack against this tumour. | Vincenza Granata Roberta Grassi Roberta Fusco Andrea Belli Raffaele Palaia Gianpaolo Carrafiello Vittorio Miele Roberto Grassi Antonella Petrillo Francesco Izzo | 2021 | World Journal of Gastroenterology2021，27，23： | 1 |
| 4 | Reduction of muscle contraction and pain in electroporation-based treatments:An overview显示文摘BACKGROUND In the first studies of electrochemotherapy(ECT),small cutaneous metastases were treated and only mild or moderate pain was observed;therefore,pain was not considered a significant issue.As the procedure began to be applied to larger cutaneous metastases,pain was reported more frequently.For that reason,reduction of both muscle contractions and pain have been investigated over the years.AIM To present an overview of different protocols described in literature that aim to reduce muscle contractions and pain caused by the electroporation(EP)effect in both ECT and irreversible EP treatments.METHODS Thirty-three studies published between January 1999 and November 2020 were included.Different protocol designs and electrode geometries that reduce patient pain and the number of muscle contractions and their intensity were analysed.RESULTS The analysis showed that both high frequency and bipolar/biphasic pulses can be used to reduce pain and muscle contractions in patients who undergo EP treatments.Moreover,adequate electrode design can decrease EP-related morbidity.Particularly,needle length,diameter and configuration of the distance between the needles can be optimised so that the muscle volume crossed by the current is reduced as much as possible.Bipolar/biphasic pulses with an inadequate pulse length seem to have a less evident effect on the membrane permeability compared with the standard pulse protocol.For that reason,the number of pulses and the voltage amplitude,as well as the pulse duration and frequency,must be chosen so that the dose of delivered energy guarantees EP efficacy.CONCLUSION Pain reduction in EP-based treatments can be achieved by appropriately defining the protocol parameters and electrode design.Most results can be achieved with high frequency and/or bipolar/biphasic pulses.However,the efficacy of these alternative protocols remains a crucial point to be assessed further. | Roberta Fusco Elio Di Bernardo Valeria D'Alessio Simona Salati Matteo Cadossi | 2021 | World Journal of Clinical Oncology2021，12，5： | 1 |
| 5 | 一种治疗勃起功能障碍的新方法:尾加压素-II受体的高亲和力受体激动剂的配体显示文摘尾加压素IIfu—111是一种通过G蛋白偶联受体发挥作用的环形多肽,主要与心血管功能相关。同时,尾加压素能量系统也与泌尿生殖道有关联。U—II能够松弛阴茎海绵体,增加阴茎海绵体内压(ICP)。因此,尾加压素II/尾加压素II受体(U.II/UTR)通路有可能成为治疗勃起功能障碍的新靶点。本研究中,我们检测了两种新型UTR的高亲和力受体激动剂P5u(H.Asp—c[Pen.Phe—Trp—Lys-ryr-Cys]一Val-OH)和UPG84(H—Asp—c[Pen—Phe—DTrp—Orn.(pNH2)Phe.Cys].Val.OH)。通过测量大鼠的ICP,分别比较了P5U、UPG84与u.II的作用。海绵窦内注射u.II(O.03—1nm01)、P5UfO.03—1nm01)、UPG84(O.03-lnmol)能够增加ICP。与U.II相比,P5U可引起ICP的显著增加。每只大鼠注射0.1nmolP5U与0.3nmolU—II的效果相当。此外,最低剂量(0.03nm01)的UPG84与最高剂量(1nm01)的u.II具有相似的效果。而且我们发现UPG84LkP5U更加有效。最低剂量(0.03nm01)的P5U对ICP无影响,而同样剂量的UPG84则可引起大鼠阴茎明显勃起。此两种化合物对血压无影响,表明其具有更高的安全性。综上,UPG84和P5U可能为治疗勃起功能障碍开启一个新的视角。 | Roberta d'Emmanuele di Villa Bianca Emma Mitidieri Erminia Donnarumma Ferdinando Fusco Nicola Longo Giuseppe De Rosa Ettore Novellino Paolo Grieco Vincenzo Mirone Giuseppe Cirino Raffaella Sorrentino | 2015 | Asian Journal of Andrology2015，17，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员